bioAffinity Faces Losses While U.S. Global Investors Profits Surge
San Antonio, Monday, 24 November 2025.
bioAffinity Technologies reported a Q3 loss of $5.05 million, doubling last year’s deficit, while U.S. Global Investors saw a 378% profit surge, reflecting stark industry contrasts.
bioAffinity Technologies: Financial Struggles Amid Revenue Decline
bioAffinity Technologies Inc. (BIAF), based in San Antonio, reported a significant financial loss for the third quarter of 2025. The company, known for developing diagnostic tests for early-stage cancer detection, posted a net loss of $5.05 million. This figure represents a substantial increase from the $2 million loss recorded in the same quarter of the previous year, effectively doubling the deficit [1]. The company’s revenue also experienced a downturn, falling to $1.45 million from $2.35 million year-over-year [1].
U.S. Global Investors: A Profitable Quarter
In contrast to bioAffinity’s downturn, U.S. Global Investors Inc., another San Antonio-based firm, reported a remarkable 378% increase in profit for its fiscal Q1 2026, compared to the previous year [1]. The investment advisory firm attributed its success to a significant 148% rise in investment income, driven by positive fund flows into its gold mining and natural resources funds [1]. This surge highlights the firm’s strategic positioning in volatile markets, particularly benefiting from the renewed interest in commodities [1].
Aramark Holdings and Market Challenges
In the service sector, Aramark Holdings Corp., the concessionaire for the Spurs at Frost Bank Center, failed to meet Wall Street expectations in its fiscal Q4. This underperformance raises concerns about its future in the competitive service industry, as it struggled to achieve anticipated net income and revenue targets [1]. The company’s performance underscores the challenges faced by service providers in adapting to the post-pandemic economic environment [1].
Adapting to Economic Realities
The contrasting fortunes of bioAffinity Technologies and U.S. Global Investors provide a snapshot of the varied economic landscape as companies navigate the complexities of post-pandemic realities. While bioAffinity struggles with declining revenues and increased losses, U.S. Global Investors capitalizes on market opportunities to maximize profits. Aramark’s challenges further illustrate the ongoing adjustments industries must make in response to evolving consumer behaviors and economic conditions [1].